ASH 2023 | Continuous PEG-asparaginase dosing reduces hypersensitivity in pediatric patients with ALL

Leiah Brigitha, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands, introduces a study (EudraCT:2012-000067-25; Dutch Trial Register NL3227) investigating the effect of continuous PEG-asparaginase dosing, without the standard asparaginase-free interval which is currently used, in pediatric patients with newly diagnosed acute lymphoblastic leukemia (ALL). PEG-asparaginase is a key component of ALL treatment. However, the use of a treatment free interval following induction leads to hypersensitivity reactions as a result of an increase in anti-drug antibodies during this period. Foregoing this interval and continuing treatment with PEG-asparaginase directly after induction led to a seven-fold decrease in the incidence of inactivating hypersensitivity reactions without increasing the rate of treatment-related toxicities or affecting treatment efficacy. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.